ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AveXis acquires former AstraZeneca facility in Colorado

by Ryan Cross
April 5, 2019 | APPEARED IN VOLUME 97, ISSUE 14

 

AveXis, the gene-therapy firm that Novartis acquired last year, plans to buy AstraZeneca’s biologics manufacturing plant in Longmont, Colorado. In January, AstraZeneca announced it would close the Longmont plant and a nearby site in Boulder, laying off 210 employees. AveXis says it will offer jobs to about 150 of those employees. AveXis anticipates US Food and Drug Administration approval in May of Zolgensma, which would be the second viral gene therapy approved in the US. AveXis already has gene-therapy manufacturing plants in Illinois, North Carolina, and California.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment